2025-03-26 12:02:25
Latest Post
Gujarat Ambuja Exports Ltd commences commercial production of Greenfield 1200 TPD Maize Processing unit
Wardwizard Promoters take decisive action with Significant Fund Infusion
EaseMyTrip signs MoU with Tourism New Zealand to strengthen travel ties and enhance Indian tourist arrivals
Welspun Corp Limited increases stake in Welspun Specialty Solutions Ltd
Rulka Electricals Secures 21 New Work Orders totaling Rs 12.36 Crore in March 2025
Stock Report
Jagsonpal Pharmaceuticals Ltd Q4 FY2023 PAT slips QoQ to Rs. 5.60 crores
Posted On : 2023-05-23 18:51:08( TIMEZONE : IST )
Jagsonpal Pharmaceuticals Limited has reported Standalone financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 58.01 crores during the period ended March 31, 2023 as compared to Rs. 61.8807 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 5.6027 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 7.7849 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 2.17 for the period ended March 31, 2023 as compared to Rs. 2.97 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹58.01 crs | ₹61.8807 crs |  -6.26% |
| Net Profit | ₹5.6027 crs | ₹7.7849 crs | -28.03% |
| EPS | ₹2.17 | ₹2.97 | -26.94% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.58.01 crores during the period ended March 31, 2023 as compared to Rs.51.5931 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.5.6027 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.0.3146 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.2.17 for the period ended March 31, 2023 as compared to Rs.0.12 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹58.01 crs | ₹51.5931 crs |  12.44% |
| Net Profit | ₹5.6027 crs | ₹0.3146 crs | 1,680.90% |
| EPS | ₹2.17 | ₹0.12 | 1,708.33% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.242.4480 crores during the Financial Year ended March 31, 2023 as compared to Rs.221.0111 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.26.7213 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.18.8563 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.10.20 for the Financial Year ended March 31, 2023 as compared to Rs.7.20 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹242.4480 crs | ₹221.0111 crs | 9.70% |
| Net Profit | ₹26.7213 crs | ₹18.8563 crs | 41.71% |
| EPS | ₹10.20 | ₹7.20 | 41.67% |
Shares of Jagsonpal Pharmaceuticals Limited was last trading in BSE at Rs. 353.95 as compared to the previous close of Rs. 353.95. The total number of shares traded during the day was 7012 in over 653 trades.
The stock hit an intraday high of Rs. 375.30 and intraday low of 349.30. The net turnover during the day was Rs. 2522549.00.
